Gene-expression profiling to predict responsiveness to immunotherapy - PubMed (original) (raw)

Review

. 2017 Mar;24(3):134-140.

doi: 10.1038/cgt.2016.63. Epub 2016 Nov 11.

Affiliations

Review

Gene-expression profiling to predict responsiveness to immunotherapy

N B Jamieson et al. Cancer Gene Ther. 2017 Mar.

Abstract

Recent clinical successes with immunotherapy have resulted in expanding indications for cancer therapy. To enhance antitumor immune responses, and to better choose specific strategies matched to patient and tumor characteristics, genomic-driven precision immunotherapy will be necessary. Herein, we explore the role that tumor gene-expression profiling (GEP) may have in the prediction of an immunotherapeutic response. Genetic markers associated with response to immunotherapy are addressed as they pertain to the tumor genomic landscape, the extent of DNA damage, tumor mutational load and tumor-specific neoantigens. Furthermore, genetic markers associated with resistance to checkpoint blockade and relapse are reviewed. Finally, the utility of GEP to identify new tumor types for immunotherapy and implications for combinatorial strategies are summarized.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare no conflict of interest

Similar articles

Cited by

References

    1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795. - PMC - PubMed
    1. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806–1814. - PubMed
    1. Maker AV. Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology. 2016;5(1):e1069937. - PMC - PubMed
    1. Maker AV, Ito H, Mo Q, Weisenberg E, Qin LX, Turcotte S, et al. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases. Cancer Immunol Res. 2015;3(4):380–388. - PMC - PubMed
    1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources